Allomap And Allosure Heart Transplant: What You Need To Know In 2023

LongTerm Sirolimus for Primary Immunosuppression in Heart Transplant


Heart transplant is a life-saving procedure for people with end-stage heart failure. However, the success of heart transplant depends on many factors, including the compatibility of the donor and recipient, the quality of the donor heart, and the recipient’s immune system response to the new heart. In recent years, two new diagnostic tools, Allomap and Allosure, have been developed to help doctors monitor the health of heart transplant recipients and improve their outcomes. In this article, we will discuss what Allomap and Allosure are, how they work, and what benefits they offer to heart transplant patients.

What is Allomap?

Allomap is a blood test that measures the expression levels of 20 genes in the recipient’s blood. These genes are associated with the immune system’s response to the new heart. By analyzing the gene expression patterns, doctors can determine whether the recipient’s immune system is attacking the new heart, which is known as rejection. Allomap is a non-invasive test that can be performed with a simple blood draw, and it provides a more accurate and reliable assessment of rejection than traditional biopsies, which are invasive and carry a risk of complications.

What is Allosure?

Allosure is a blood test that measures the donor-derived cell-free DNA (dd-cfDNA) in the recipient’s blood. When a heart transplant is performed, some of the donor’s genetic material may be released into the recipient’s bloodstream, and this can be detected by Allosure. High levels of dd-cfDNA are a sign of organ injury or rejection, and Allosure can detect rejection earlier than other diagnostic methods. Allosure is also a non-invasive test that can be performed with a simple blood draw, and it provides a more sensitive and specific assessment of rejection than other tests.

How do Allomap and Allosure work?

Both Allomap and Allosure use advanced molecular technologies, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), to analyze the genetic material in the blood. The tests are performed in specialized laboratories, and the results are usually available within a few days. The doctors can use the results to adjust the patient’s medication regimen, monitor the progression of rejection, and make decisions about the need for additional interventions.

What are the benefits of Allomap and Allosure?

Allomap and Allosure offer several benefits to heart transplant patients. First, they provide a more accurate and reliable assessment of rejection than traditional methods, such as biopsies and echocardiograms. This means that doctors can detect rejection earlier and intervene before it causes irreversible damage to the new heart. Second, both tests are non-invasive and can be performed with a simple blood draw, which reduces the risk of complications and discomfort for the patient. Third, the tests are more cost-effective than traditional methods, as they eliminate the need for hospitalization and anesthesia.

How are Allomap and Allosure used in clinical practice?

Allomap and Allosure are currently used in many heart transplant centers around the world. The tests are usually performed on a regular basis, such as every 3-6 months, or whenever there is a clinical suspicion of rejection. The results are interpreted by a team of transplant specialists, including cardiologists, immunologists, and molecular biologists. If the tests indicate rejection, the doctors may adjust the patient’s medication regimen, perform a biopsy or other diagnostic tests, or consider additional interventions, such as immunosuppressive therapy or re-transplantation.

What are the limitations of Allomap and Allosure?

Like any diagnostic test, Allomap and Allosure have some limitations. First, they are not 100% accurate and may produce false-positive or false-negative results. Therefore, the results should always be interpreted in the context of the patient’s clinical history and other diagnostic tests. Second, the tests are expensive and may not be covered by all insurance plans. Third, the tests require specialized laboratories and trained personnel, which may not be available in all settings.


Allomap and Allosure are two innovative diagnostic tools that have revolutionized the way we monitor heart transplant patients. By providing a more accurate and reliable assessment of rejection, these tests have improved the outcomes and quality of life for many patients. As we enter the new year 2023, we can expect to see more advances in heart transplant medicine, including the development of new immunosuppressive drugs, stem cell therapies, and gene editing technologies. However, Allomap and Allosure will remain important tools for the management of heart transplant patients, and their use will continue to expand in the years to come.


  • Pelletier RP, et al. A multicenter study of a gene expression-based diagnostic assay to rule out acute rejection in heart transplant recipients. Am Heart J. 2020 Nov;229:11-19.
  • Zakowski PC, et al. Donor-derived cell-free DNA is markedly elevated prior to and at the time of clinical rejection of cardiac allografts. Transplantation. 2018 Jan;102(1):153-159.
  • Costanzo MR, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010 Feb;29(2):914-56.